Drugs / QG101-23-0
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05650528 | Mar 2023 → Jan 2024 | — | Amckaus PTY LTD. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07675668 | Oct 2026 → Dec 2027 expected | hypertrophic cardiomyopathy | Amckaus PTY LTD. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QG101-23-0 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05650528 ↗ |
| Route | Oral | “administration through oral” NCT05650528 ↗ |